Table 4 Univariate analysis and multivariate logistic regression analysis in individuals with type 2 diabetes mellitus.
From: FGF21 is a novel biomarker to predict fragility fractures in patients with type 2 diabetes mellitus
Any fracture N (%) | Univariate analysis | Logistic regression | |||||
|---|---|---|---|---|---|---|---|
OR | 95% CI | P-value | AOR | 95% CI | P-value | ||
FGF21 (pg/mL) (per 10-unit) | 21 (12.1) | 0.97 | 0.93–0.998 | 0.040 | 0.94 | 0.90–0.99 | 0.021 |
Age (years) | 21 (10.3) | 1.05 | 0.99–1.10 | 0.084 | 1.13 | 1.04–1.22 | 0.005 |
Sex | |||||||
Male | 4 (4.4) | Ref. | Ref. | ||||
Female | 17 (15.0) | 3.81 | 1.23–11.76 | 0.020 | 5.06 | 1.41–18.12 | 0.013 |
CVD (%) | |||||||
No | 18 (14.0) | Ref. | |||||
Yes | 3 (4.1) | 0.26 | 0.07–0.92 | 0.036 | |||
BMI-based FRAX-M (%) | 21 (10.3) | 0.92 | 0.78–1.07 | 0.257 | 0.77 | 0.60–0.99 | 0.042 |
HDL-C (mg/dL) | 21 (10.8) | 1.03 | 1.00–1.06 | 0.079 | |||
LDL-C (mg/dL) | 21 (10.8) | 0.99 | 0.98–1.00 | 0.156 | |||
AST (U/L) | 19 (10.0) | 0.95 | 0.89–1.01 | 0.123 | 0.96 | 0.90–1.02 | 0.162 |
Insulin | |||||||
No | 7 (6.5) | Ref. | |||||
Yes | 14 (14.7) | 2.49 | 0.96–6.47 | 0.060 | |||
Sulfonylureas | |||||||
No | 15 (12.8) | Ref. | |||||
Yes | 6 (7.0) | 0.51 | 0.19–1.37 | 0.183 | |||
Beta-blockers | |||||||
No | 16 (15.2) | Ref. | |||||
Yes | 5 (5.1) | 0.30 | 0.11–0.85 | 0.024 | |||
Statin | |||||||
No | 1 (3.6) | Ref. | |||||
Yes | 20 (11.4) | 3.48 | 0.45–27.05 | 0.233 | |||
